Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 1, 2024
Biofilms
are
intricate
microbial
communities
on
various
surfaces,
including
medical
devices
and
biological
tissues,
encased
within
a
protective
matrix
of
extracellular
polymeric
substances.
Their
formation
persistence
significant
factors
in
the
pathogenesis
chronic
infections,
contributing
to
complexity
treatment
increased
resistance
antimicrobial
agents.
This
review
explores
multifaceted
nature
biofilms,
focusing
their
formation,
structure,
genetic
environmental
that
contribute
resilience.
particularly
problematic
such
as
those
associated
with
implants
persistent
wounds,
due
ability
evade
both
host
immune
response
conventional
therapeutic
strategies.
The
also
discusses
current
challenges
diagnosing
biofilm-associated
infections
limitations
existing
options.
Emerging
approaches,
novel
antibiofilm
agents,
physical
disruption
techniques,
therapies
phage
therapy,
examined
for
potential
improve
outcomes.
Innovations
drug
delivery
systems
preventive
measures,
biofilm-resistant
materials,
highlighted
promising
developments.
comprehensive
overview
aims
provide
insights
into
mechanisms
biofilm-related
guide
future
research
clinical
practice.
contributes
ongoing
efforts
enhance
patient
care
combat
growing
challenge
by
addressing
critical
need
effective
strategies
manage
prevent
infections.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(4), P. 470 - 470
Published: April 8, 2024
Methicillin-resistant
Staphylococcus
aureus
(M
RSA)
infections,
in
particular
biofilm-organized
bacteria,
remain
a
clinical
challenge
and
serious
health
problem.
Rifabutin
(RFB),
an
antibiotic
of
the
rifamycins
class,
has
shown
previous
work
excellent
anti-staphylococcal
activity.
Here,
we
proposed
to
load
RFB
liposomes
aiming
promote
accumulation
at
infected
sites
consequently
enhance
therapeutic
potency.
Two
isolates
MRSA,
MRSA-C1
MRSA-C2,
were
used
test
developed
formulations,
as
well
positive
control,
vancomycin
(VCM).
free
liposomal
forms
displayed
high
antibacterial
activity,
with
similar
potency
between
tested
formulations.
In
MRSA-C1,
minimal
inhibitory
concentrations
(MIC)
for
Free
0.009
0.013
μg/mL,
respectively.
Minimum
biofilm
able
inhibit
50%
growth
(MBIC50)
against
0.012
0.008
Confocal
microscopy
studies
demonstrated
rapid
internalization
unloaded
RFB-loaded
bacterial
matrix.
murine
models
systemic
infection,
Balb/c
mice
treated
formulations
VCM
20
40
mg/kg
body
weight,
The
vivo
results
significant
reduction
burden
index
major
organs
compared
Control
(positive
control)
groups.
Furthermore,
dose
was
two
fold
higher
than
one
reinforcing
strategy.
addition,
only
associated
100%
survival.
Globally,
this
study
emphasizes
potential
nanoformulations
effective
safe
approach
MRSA
infections.
Critical Reviews in Microbiology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 40
Published: Feb. 29, 2024
Antibiotics
have
remained
the
cornerstone
for
treatment
of
bacterial
infections
ever
since
their
discovery
in
twentieth
century.
The
uproar
over
antibiotic
resistance
among
bacteria
arising
from
genome
plasticity
and
biofilm
development
has
rendered
current
therapies
ineffective,
urging
innovative
therapeutic
approaches.
further
heightened
clinical
failure
therapy,
which
is
often
linked
to
its
low
bioavailability,
side
effects,
poor
penetration
accumulation
at
site
infection.
In
this
review,
we
highlight
potential
use
siderophores,
antibodies,
cell-penetrating
peptides,
antimicrobial
bacteriophages,
nanoparticles
smuggle
antibiotics
across
impermeable
biological
membranes
achieve
therapeutically
relevant
concentrations
combat
(AMR).
We
will
discuss
general
mechanisms
via
each
delivery
system
functions
how
it
can
be
tailored
deliver
against
paradigm
underlying
resistance.
Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 1, 2024
Biofilms
are
intricate
microbial
communities
on
various
surfaces,
including
medical
devices
and
biological
tissues,
encased
within
a
protective
matrix
of
extracellular
polymeric
substances.
Their
formation
persistence
significant
factors
in
the
pathogenesis
chronic
infections,
contributing
to
complexity
treatment
increased
resistance
antimicrobial
agents.
This
review
explores
multifaceted
nature
biofilms,
focusing
their
formation,
structure,
genetic
environmental
that
contribute
resilience.
particularly
problematic
such
as
those
associated
with
implants
persistent
wounds,
due
ability
evade
both
host
immune
response
conventional
therapeutic
strategies.
The
also
discusses
current
challenges
diagnosing
biofilm-associated
infections
limitations
existing
options.
Emerging
approaches,
novel
antibiofilm
agents,
physical
disruption
techniques,
therapies
phage
therapy,
examined
for
potential
improve
outcomes.
Innovations
drug
delivery
systems
preventive
measures,
biofilm-resistant
materials,
highlighted
promising
developments.
comprehensive
overview
aims
provide
insights
into
mechanisms
biofilm-related
guide
future
research
clinical
practice.
contributes
ongoing
efforts
enhance
patient
care
combat
growing
challenge
by
addressing
critical
need
effective
strategies
manage
prevent
infections.
